The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase I/II trial of two schedules of bortezomib and bevacizumab (BBmibmab) in metastatic renal cell cancer: USC trial 4K-05-1.
 
David I. Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Fresenius Kabi; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Algeta/Bayer; Astellas Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
Expert Testimony - Medivation; Teva
 
Denice Wei
No Relationships to Disclose
 
Kristy Massopust
No Relationships to Disclose
 
Charlean Ketchens
No Relationships to Disclose
 
James Hu
No Relationships to Disclose
 
Amir Goldkorn
No Relationships to Disclose
 
Ana Aparicio
Honoraria - Sanofi
Consulting or Advisory Role - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Sarmad Sadeghi
No Relationships to Disclose
 
Jacek K. Pinski
No Relationships to Disclose
 
Monica Averia
No Relationships to Disclose
 
Susan G. Groshen
Employment - Pfizer (I)
 
Tanya B. Dorff
Honoraria - Astellas Pharma; Bayer; Medivation; Myriad Genetics; Pfizer; Sanofi
Consulting or Advisory Role - Dendreon; Genentech
Speakers' Bureau - Astellas Pharma; Bayer; Pfizer
Research Funding - Bristol-Myers Squibb